Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

LIXT Lixte Biotechnology Holdings Inc

2,3381

0,0081 (0,35%)

01 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Lixte Biotechnology Charts.

Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Lixte Biotechnology Charts.

News Lixte Biotechnology Holdings Inc

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
Mittwoch 8 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Mixed Shelf Filing Gives Micro Cap Delayed Boost
Mittwoch 24 April 2024 (1 Monat vor) • AllPennyStocks.com

Biotech Steals The Show Following Pre-Clinical Data Announcement
Mittwoch 27 März 2024 (2 Monate vor) • AllPennyStocks.com

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
Mittwoch 27 März 2024 (2 Monate vor) • GlobeNewswire Inc.

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
Donnerstag 21 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 27 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
Dienstag 27 Februar 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Montag 26 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Montag 26 Februar 2024 (3 Monate vor) • GlobeNewswire Inc.

First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
Montag 29 Januar 2024 (4 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 28 November 2023 (6 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Montag 13 November 2023 (7 Monate vor) • Edgar (US Regulatory)

Weitere Lixte Biotechnology Holdings Inc News-Artikel

AB US High Dividend ETF

NLBNPIT21CV1 20240621 37...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen